Literature DB >> 24795292

Changing roles of eosinophils in health and disease.

Glenn T Furuta1, F Dan Atkins2, Nancy A Lee3, James J Lee4.   

Abstract

OBJECTIVE: To review and highlight the unappreciated roles of eosinophils suggested by recent studies. DATA SOURCES: The literature, unpublished observations, and insights by the authors. STUDY SELECTIONS: Basic studies of mouse models and patient-based clinical studies of disease.
RESULTS: Eosinophils are often thought of as destructive end-stage effector cells primarily linked to parasite host defense and dysregulated immune responses associated with allergic diseases, such as asthma. However, recent studies (ie, research focused on mechanisms of action and translational studies examining disease/inflammatory pathways) are suggesting far more complex roles for eosinophils. The goal of this review is 3-fold. (1) The authors examine the dynamic history of eosinophils and how physicians over time used this information to formulate defining hypotheses. Particular emphasis is placed on recent studies challenging the parochial view of host defense in favor of roles maintaining homeostasis through immune modulation and tissue remodeling/repair. (2) They discuss diagnostic approaches to assess eosinophils in clinical settings as a means of disease identification and subsequently as a measurement of disease severity. (3) They examine how contemporary views of eosinophils and their perceived roles in diseases have led to specific therapeutic strategies. The emphasis is to review the successes and failures of these strategies as the basis of formulating future clinical studies targeting eosinophils as potential therapies of disease.
CONCLUSION: Despite the complexities of eosinophil-mediated activities and the less than overwhelming success of initial attempts targeting these cells, eosinophils remain a potentially important focal target of disease diagnosis and subsequent treatment strategies.
Copyright © 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24795292      PMCID: PMC4065823          DOI: 10.1016/j.anai.2014.04.002

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  75 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

2.  Eosinophils in asthma--closing the loop or opening the door?

Authors:  Sally E Wenzel
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

3.  Mechanism of membrane damage mediated by human eosinophil cationic protein.

Authors:  J D Young; C G Peterson; P Venge; Z A Cohn
Journal:  Nature       Date:  1986 Jun 5-11       Impact factor: 49.962

4.  Cytotoxic properties of the eosinophil major basic protein.

Authors:  G J Gleich; E Frigas; D A Loegering; D L Wassom; D Steinmuller
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

5.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

6.  Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis.

Authors:  K J Hamann; R L Barker; D A Loegering; G J Gleich
Journal:  J Parasitol       Date:  1987-06       Impact factor: 1.276

7.  The ECP/Eo count ratio in children with asthma.

Authors:  Iwona Stelmach; Pawel Majak; Tomasz Grzelewski; Joanna Jerzynska; Dorota Jurałowicz; Wlodzimierz Stelmach; Malgorzata Borzecka-Podsiadlowicz; Aleksandra Korzeniewska; Piotr Kuna
Journal:  J Asthma       Date:  2004-08       Impact factor: 2.515

8.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

9.  Epithelial injury by human eosinophils.

Authors:  P Venge; R Dahl; K Fredens; C G Peterson
Journal:  Am Rev Respir Dis       Date:  1988-12

10.  Eosinophil deficiency compromises parasite survival in chronic nematode infection.

Authors:  Valeria Fabre; Daniel P Beiting; Susan K Bliss; Nebiat G Gebreselassie; Lucille F Gagliardo; Nancy A Lee; James J Lee; Judith A Appleton
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

View more
  37 in total

Review 1.  Eosinophilic Skin Diseases: A Comprehensive Review.

Authors:  Hai Long; Guiying Zhang; Ling Wang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

2.  Understanding allergic multimorbidity within the non-eosinophilic interactome.

Authors:  Daniel Aguilar; Nathanael Lemonnier; Gerard H Koppelman; Erik Melén; Baldo Oliva; Mariona Pinart; Stefano Guerra; Jean Bousquet; Josep M Anto
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

3.  Cytokine Diversity in Human Peripheral Blood Eosinophils: Profound Variability of IL-16.

Authors:  Michelle Ma; Caroline M Percopo; Daniel E Sturdevant; Albert C Sek; Hirsh D Komarow; Helene F Rosenberg
Journal:  J Immunol       Date:  2019-06-10       Impact factor: 5.422

Review 4.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 5.  Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.

Authors:  Mahsa Eskian; MirHojjat Khorasanizadeh; Amal H Assa'ad; Nima Rezaei
Journal:  Clin Rev Allergy Immunol       Date:  2018-08       Impact factor: 8.667

6.  Blockade of equilibrative nucleoside transporter 1/2 protects against Pseudomonas aeruginosa-induced acute lung injury and NLRP3 inflammasome activation.

Authors:  Eboni D Chambers; Alexis White; Alexander Vang; Zhengke Wang; Alfred Ayala; Tingting Weng; Michael Blackburn; Gaurav Choudhary; Sharon Rounds; Qing Lu
Journal:  FASEB J       Date:  2019-12-02       Impact factor: 5.191

7.  Treatment of Disseminated Talaromyces marneffei with Tracheal Infection: Two Case Reports.

Authors:  Ye Qiu; DeCheng Lu; Jianquan Zhang; Xiaoning Zhong; Guangnan Liu; Bixun Li
Journal:  Mycopathologia       Date:  2015-04-12       Impact factor: 2.574

Review 8.  Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.

Authors:  Diego Bagnasco; Matteo Ferrando; Marco Caminati; Alice Bragantini; Francesca Puggioni; Gilda Varricchi; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

Review 9.  The Role of the Environment in Eosinophilic Esophagitis.

Authors:  Paul J Dowling; Hannah Neuhaus; Brooke I Polk
Journal:  Clin Rev Allergy Immunol       Date:  2019-12       Impact factor: 8.667

10.  Lung-resident eosinophils represent a distinct regulatory eosinophil subset.

Authors:  Claire Mesnil; Stéfanie Raulier; Geneviève Paulissen; Xue Xiao; Mark A Birrell; Dimitri Pirottin; Thibaut Janss; Philipp Starkl; Eve Ramery; Monique Henket; Florence N Schleich; Marc Radermecker; Kris Thielemans; Laurent Gillet; Marc Thiry; Maria G Belvisi; Renaud Louis; Christophe Desmet; Thomas Marichal; Fabrice Bureau
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.